<mainarticle> ... </article> <relatedarticles> ... </article> <relatedarticle> ... </article> {{section>:&noheader&firstseconly}} (({{pmid>long:}})) {{backlinks>.}} {{topic>papers presentations -+}}
1. Emergency Is this an emergency?
2. Light exposure Patients on the Marshall Protocol may find their symptoms become worse after exposing their eyes to indoor light or sunlight, or exposing their skin to sunlight. A reaction may occur within several seconds or may take as long as 24-48 hours to occur.
Did disease symptoms increase following light exposure? (Yes | No) * If yes:
* If no, question 3.
3. Antibiotic doses Increases in the dose of Marshall Protocol antibiotics often corresponds to an increase in immunopathology/herx.
Has the patient recently increased his or her dose of antibiotics? (Yes | No) * If yes: Marshall Protocol patients who are experiencing intolerable immunopathologyAn unbearable or unsafe severity of bacterial die-off reaction. should decrease their dose of antibiotics to the last dose at which they were experiencing tolerable immunopathologyA state in which a patient has maintained an acceptable intensity of bacterial die-off reaction. The primary goal of the Marshall Protocol.. As straightforward as this advice may sound, the choice to reduce one's antibiotics is one that a number of patients have difficulty making. Decreasing one's antibiotics is not an admission of defeat. MP patients can make progress at any dose of antibiotics. * If no, question 4.
# | ID | Title |
---|---|---|
1 | home | Welcome to the MPKB |
2 | home:arf | Autoimmunity Research Foundation |
3 | home:arf:donate | Donate |
4 | home:arf:press_releases | Press releases |
5 | home:arf:privacy | Privacy policy |
6 | home:devel | Development |
7 | home:devel:1 | Home |
8 | home:devel:17 | |
9 | home:devel:5555 | |
10 | home:devel:6 | Home |
11 | home:devel:6b | Home |
12 | home:devel:6c | Home |
13 | home:devel:6d | |
14 | home:devel:8 | |
15 | home:devel:customizations | Customizations |
16 | home:devel:eyes | Intracellular microbes in opthalmic disease: a reappraisal |
17 | home:devel:framework | Framework for managing the stages of recovery |
18 | home:devel:legacyindex | Marshall Protocol Legacy Link Index |
19 | home:devel:logo | Logos |
20 | home:devel:quiz | |
21 | home:devel:quizsource | Quiz title |
22 | home:devel:studydesign | Markers for Study Design |
23 | home:devel:styleguide | Style Guidelines and Best Practices |
24 | home:diseases:addisons | Addison's disease |
25 | home:diseases:als | ALS (Lou Gehrig's Disease) |
26 | home:diseases:cat_scratch | Cat scratch fever |
27 | home:diseases:cystic_fibrosis | Cystic fibrosis |
28 | home:diseases:diabetes1 | Diabetes, Type I |
29 | home:diseases:endometriosis | Endometriosis |
30 | home:diseases:hlh | Hemophagocytic lymphohistiocytosis (HLH) |
31 | home:diseases:hypercalcemia | Hypercalcemia (hypercalcaemia) |
32 | home:diseases:learning | Learning difficulties (ADHD, ADD, dyslexia) |
33 | home:diseases:lyme | Chronic Lyme disease |
34 | home:diseases:members | Members & Diagnoses |
35 | home:diseases:osteoarthritis | Osteoarthritis |
36 | home:diseases:raynauds | Raynaud's phenomenon |
37 | home:diseases:reactive_arthritis | Reactive arthritis (Reiter's syndrome) |
38 | home:diseases:sjogrens | Sjogren's syndrome |
39 | home:immune_suppression_today | Immune suppressive environments |
40 | home:mp:expiration | Expiration date of medications |
41 | home:mp:modifying | Modifying the Marshall Protocol |
42 | home:othertreatments:antimetabolites | Antimetabolite |
43 | home:othertreatments:antimetabolites:methotrexate | Methotrexate (MTX) |
44 | home:othertreatments:frankincense | Frankincense |
45 | home:othertreatments:immune_suppressants | Immune Suppression |
46 | home:othertreatments:immune_suppressants:anti-tnf_drugs | Anti-TNF drugs |
47 | home:othertreatments:immune_suppressants:corticosteroids | Corticosteroids |
48 | home:othertreatments:iodine | Iodine |
49 | home:othertreatments:salvestrols | Salvestrols |
50 | home:othertreatments:sample_page | sample page layout |
51 | home:publications:mangin_days_of_molecular_medicine_2008 | Poster - Monitoring cognitively-impaired subjects in an interactive Internet-based clinical trial of a multi-factorial treatment based on a molecular model of chronic disease |
52 | home:publications:waterhouse_mp_for_lyme_2007 | Article - The Marshall Protocol for Lyme Disease and other chronic inflammatory conditions |
53 | home:search | Search the MPKB |
54 | home:search2 | Search the MPKB |
55 | home:social | Social and psychological aspects |
56 | home:social:the_vagus_nerve | The vagus nerve |
57 | home:special:emf:measure:looking4 | Looking for sources of Radio Frequency Radiation |
58 | home:special:kidneys_at_work | Kidneys at Work |
59 | home:special:optometrist | Working with an optometrist |
60 | home:starting:usingforum:support:insurance | Volunteer insurance protection |
61 | home:symptoms | Symptoms |
62 | home:symptoms:ears | Ear symptoms |
63 | home:symptoms:gastrointestinal | Gastrointestinal symptoms |
64 | home:symptoms:hormonal:home | Hormonal symptoms |
65 | home:symptoms:lymph | Swollen lymph glands |
66 | home:symptoms:muscle_bone | Muscle and bone symptoms |
67 | home:symptoms:neurological:paresthesia | Numbness (paresthesia and neuropathy) |
68 | home:symptoms:nosebleeds | Nosebleeds |
69 | home:symptoms:other | Other symptoms |
70 | home:symptoms:urinary | Urinary symptoms |
71 | home:videos | Members-Only Videos |
72 | home:waves:aim_health:mental | Mental Health |
73 | home:waves:devp_outline | Outline of work in progress |
74 | home:waves:devp_outline:whitezonesbk | White zones |
75 | home:waves:explanations | Explanations |
76 | home:waves:glossary | |
77 | home:waves:grounding | Grounding |
78 | home:waves:hardware | Mitigating hardware emissions |
79 | home:waves:mitigation_steps | Step by step mitigation |
80 | home:waves:trudy | Trudy's Esmog content creation notes |
81 | ncbi_esummary:home | |
82 | playground:checkout | |
83 | playground:checkout:digestion | Digestion |
84 | playground:checkout:french | Protocole Marshall (traduction Française) |
85 | playground:checkout:german | Marshall Protocol (Deutsche übersetzung) |
86 | playground:checkout:j_other | The Healthy Kidney at Work |
87 | playground:checkout:netherlands | Marshall Protocol (Nederlandse vertaling) |
88 | playground:checkout:pathogenesis:2 | Th1 Spectrum Disorder (copy of unedited pathogenesis/2) |
89 | playground:checkout:polish | Protokół Marshalla (tłumaczenie na Polski) |
90 | playground:checkout:publications:proal_discoverymedicine_2017 | Paper - Microbe-microbe and host-microbe interactions drive microbiome dysbiosis and inflammatory processes. |
91 | playground:checkout:q_other | saved ...Jigsaw posts |
92 | playground:checkout:retired:outline | Radio Frequency Radiation |
93 | playground:checkout:retired:overview | Overview |
94 | playground:checkout:retired:waves:measuring:meters:home | Modifying Home Environment |
95 | playground:checkout:spanish | El Protocolo Marshall (en Español) |
96 | playground:checkout:template | to template |
97 | playground:checkout:testing | Q here |
98 | playground:checkout:testing123 | Testing123 |
99 | playground:checkout:testing:pppm | Predictive, Preventative and Personalised Medicine |
100 | playground:checkout:testing:telmisartan | Telmisartan |
101 | playground:checkout:the_raas_system | The renin-angiotensin-aldosterone system (RAAS) |
102 | playground:checkout:the_ras_system | The RAAS system |
103 | playground:checkout:trainee_play_area | Trainee developer play area |
104 | playground:contributors | Level 1 Headline |
105 | playground:index | playground index experiment |
106 | playground:newpage | table of D findings |
107 | playground:present | Presentation |
108 | playground:template | Sample page layout |
109 | wiki:welcome | Welcome to your new DokuWiki |
?do=backlink